Johns Hopkins Researchers Develop Novel Intranasal DNA Vaccine Targeting Drug-Tolerant Tuberculosis

Researchers at Johns Hopkins Medicine and the Johns Hopkins Bloomberg School of Public Health have achieved a significant breakthrough in the fight against tuberculosis (TB), developing an experimental therapeutic DNA vaccine delivered intranasally. This innovative vaccine is specifically engineered to bolster the immune system’s capacity to identify and neutralize drug-tolerant TB bacteria, commonly referred to as "persisters." These resilient microbes are notorious for surviving prolonged antibiotic treatments, posing a formidable challenge to eradication efforts and frequently triggering disease relapse in patients. The groundbreaking findings, which offer a potential paradigm shift in TB treatment strategies, were formally published in the esteemed Journal of Clinical Investigation.

The development marks a crucial step forward in addressing one of humanity’s most ancient and persistent health scourges. Tuberculosis has plagued human populations for millennia, with archaeological evidence suggesting its presence dating back at least 6,000 years. Despite significant medical advancements, it continues to rank among the world’s deadliest infectious diseases. The World Health Organization (WHO) estimates a staggering one-quarter of the global population—approximately 2 billion individuals—harbor latent TB infections, remaining asymptomatic but at risk of developing active disease. In 2024 alone, over 10 million people developed active TB, and a tragic 1.2 million succumbed to the illness, solidifying its position as the leading cause of death from a single infectious pathogen worldwide. This stark reality underscores the urgent and ongoing need for novel, more effective therapeutic interventions.

The Enduring Global Burden of Tuberculosis: A Historical and Contemporary Perspective

Tuberculosis is caused by the bacterium Mycobacterium tuberculosis and primarily affects the lungs, though it can impact any part of the body. Its insidious nature lies in its ability to remain dormant for years, even decades, before reactivating. Historically, TB, often romanticized as "consumption," decimated populations, particularly in crowded urban environments during the industrial revolution. The discovery of streptomycin in the 1940s heralded the antibiotic era, offering the first effective treatment. However, the subsequent decades revealed the formidable adaptive capacity of M. tuberculosis, leading to the emergence of drug resistance.

Today, the global fight against TB is complicated by several factors. The sheer scale of latent infection represents a vast reservoir for future active cases. Furthermore, the standard treatment regimen for active TB is notoriously arduous, typically involving a combination of multiple antibiotics taken for six to nine months. For drug-resistant forms, treatment can extend to two years or more, involving more toxic and less effective drugs. This lengthy and complex regimen often leads to poor patient adherence, contributing to treatment failures and the further evolution of drug-resistant strains, including multidrug-resistant (MDR-TB) and extensively drug-resistant (XDR-TB) forms. These resistant strains are significantly harder and more expensive to treat, with much lower success rates, creating a vicious cycle that perpetuates the pandemic. The WHO has repeatedly emphasized that current strategies are insufficient to meet the ambitious goal of ending the TB epidemic by 2030, necessitating innovative approaches, particularly therapeutic vaccines that can complement existing drug treatments.

Addressing Unmet Needs: The Strategic Importance of Therapeutic Vaccines

The WHO’s call for therapeutic vaccines is a recognition of the limitations of current strategies. Such vaccines are envisioned not as replacements for antibiotics but as powerful adjuncts that could drastically shorten the duration of treatment regimens, improve patient outcomes, and potentially prevent relapse. This is particularly critical given the challenges associated with multidrug therapies, which can be difficult for patients to complete dueance to side effects and the sheer length of treatment, and the relentless spread of drug-resistant forms of TB.

The new Johns Hopkins study suggests that their experimental vaccine approach could offer a viable solution to these pressing challenges. "Administered together with first-line TB drug therapy, our intranasal DNA fusion vaccine helped infected mice clear the disease bacteria faster, reduced lung inflammation and prevented relapse after treatment ended," stated Dr. Styliani Karanika, study lead author and a faculty member of the Johns Hopkins Center for Tuberculosis Research and assistant professor of medicine at the Johns Hopkins University School of Medicine. She further highlighted the vaccine’s potential in combating drug-resistant strains: "The vaccine also helped the powerful TB drug combination of bedaquiline, pretomanid and linezolid work better, suggesting it could be used with treatments against drug-resistant TB to help the body fight the disease, even hard-to-treat cases." This finding is particularly significant, as it indicates the vaccine’s potential to enhance the efficacy of drugs used against some of the most intractable forms of TB.

Deciphering the Mechanism: How the Experimental TB Vaccine Works

The innovative design of this experimental TB vaccine lies in its ability to specifically target "persister" bacteria. These are not genetically resistant strains but rather a subpopulation of M. tuberculosis that enters a metabolically dormant, drug-tolerant state, making them largely impervious to antibiotics that typically target actively replicating bacteria. Eliminating these persisters is crucial for achieving a complete cure and preventing relapse.

According to Dr. Karanika, the vaccine achieves its therapeutic effect by combining two specific genes: relMtb and Mip3α. The delivery method, intranasal administration, is also a critical component, leveraging several biological mechanisms to strengthen immunity against TB.

The first key component is the relMtb gene. "TB bacteria possess a gene, relMtb, that produces a protein, RelMtb, to help the microbes survive hostile conditions such as antibiotic exposure, low oxygen and nutrient limitation by entering a drug-tolerant persistent state," Dr. Karanika explained. This protein is essentially the bacteria’s survival switch, enabling it to evade destruction. By incorporating the relMtb gene into the vaccine, the researchers aim to present this critical survival protein to the immune system.

The second component, Mip3α, is a chemokine gene that plays a vital role in immune cell recruitment. "Fusing relMtb with the Mip3α gene produces a signal that attracts immature dendritic cells — key cells that pick up TB proteins and ‘present’ them to T cells, the immune cells that help coordinate a targeted attack on the TB bacteria," Dr. Karanika elaborated. Dendritic cells act as "sentinels" of the immune system, capturing antigens (like the RelMtb protein) and migrating to lymph nodes to activate T cells. T cells, in turn, are crucial for cell-mediated immunity, with CD4 (helper T cells) orchestrating the immune response and CD8 (killer T cells) directly destroying infected cells. By attracting dendritic cells, the vaccine ensures efficient processing and presentation of the RelMtb protein, thereby priming a robust and specific T-cell response against the persister bacteria.

Finally, the intranasal delivery route is a strategic choice. "Intranasal delivery focuses vaccination on the respiratory mucosa in the lungs where TB infection occurs, helping generate long-lasting localized T-cell immunity in the airways and lungs, along with systemic immune responses," Dr. Karanika stated. The respiratory tract is the primary entry point and site of initial infection for TB. By delivering the vaccine directly to this mucosal surface, the researchers aim to stimulate a strong, localized immune response that can rapidly detect and eliminate TB bacteria in the lungs, where the battle against the pathogen is most critical. This localized immunity, combined with systemic responses, provides a dual layer of defense.

Promising Preclinical Results: Insights from Animal Studies

The effectiveness of this multi-pronged approach was rigorously evaluated in preclinical animal models. In mouse experiments, the vaccine demonstrated remarkable results. It significantly increased the recruitment and activation of dendritic cells within the lung tissue, facilitating their critical role in antigen presentation. Furthermore, the vaccine improved the spatial organization of dendritic cells and T cells within the lung tissue, creating an optimal environment for immune cell interaction and activation. Crucially, it generated durable, antigen-stimulated T-cell responses—both locally within the lungs and systemically throughout the body—from both CD4 (helper T cells) and CD8 (killer T cells). These findings collectively indicate a potent and sustained immune activation specifically geared towards combating TB.

Building on the success in mice, the team extended their evaluation to rhesus macaques, an animal model whose immune system more closely mirrors that of humans, providing a crucial bridge to human clinical trials. In these nonhuman primates, the nose-delivered DNA vaccine successfully generated measurable TB-specific immune responses in both the bloodstream and the airways. These responses were observed to be similar in profile to those associated with reduced bacterial levels in the lungs of vaccinated mice, suggesting a comparable protective mechanism.

Researchers observed that these immune responses in macaques lasted for at least six months, indicating the potential for durable protection—a highly desirable characteristic for any vaccine. However, Dr. Karanika prudently noted an important limitation of the primate study: it assessed immune activation only and did not test how the animals responded to an actual TB infection. This means while the vaccine effectively stimulated the immune system, its direct protective efficacy against live TB infection in macaques remains to be formally tested. She emphasized that additional research will be required before the vaccine can advance to human clinical trials.

"These nonhuman primate data are encouraging because they show that the Mip3α/relMtb vaccine can generate durable, antigen-stimulated immune responses in an animal model whose immune system more closely resembles that of humans," Dr. Karanika explained. "That gives us an important translational bridge between the mouse efficacy studies and the additional preclinical work needed before human trials." This careful progression through animal models is standard in vaccine development, ensuring safety and efficacy before human subjects are involved.

The Broader Implications: Targeting TB Persisters with Immunotherapy

The researchers firmly believe that their results lend strong support to a broader, evolving treatment strategy for TB. This strategy advocates for focusing on the elimination of TB persisters through immunotherapy, rather than relying exclusively on antibiotics that primarily target actively growing bacteria. This shift in focus is critical because the persistence of these dormant bacteria is a major reason for the lengthy treatment regimens and the high rate of relapse.

The choice of a DNA vaccine platform also offers practical advantages. DNA vaccines are generally known for their stability, ease of manufacture, and potential for efficient production. If future studies in humans demonstrate similar benefits, this approach could offer a scalable and cost-effective solution, particularly valuable in resource-limited settings where TB is most prevalent. This could potentially revolutionize how TB is managed globally, offering a more complete and lasting cure.

Timeline and Milestones in TB Vaccine Research

The journey of TB vaccine development has been long and challenging. The only currently licensed TB vaccine, Bacillus Calmette-Guérin (BCG), was developed over a century ago (first used in humans in 1921). While BCG offers some protection against severe forms of TB in children, its efficacy against adult pulmonary TB, the most common and infectious form, is highly variable and generally poor. This significant gap has driven decades of research into new vaccine candidates.

The Johns Hopkins research represents a crucial step in this ongoing effort, moving from initial conceptualization and gene identification to successful preclinical validation in complex animal models. The progression from in vitro studies to mouse models, and then to nonhuman primate studies, follows a standard and rigorous timeline in vaccine development, each stage providing more complex and translational data. The next critical milestone will be the transition to human clinical trials, which will involve phases to assess safety (Phase 1), immunogenicity and preliminary efficacy (Phase 2), and large-scale efficacy (Phase 3). This process is typically lengthy, often spanning several years, but is essential for bringing a new vaccine to patients.

Expert Perspectives and Future Outlook

The scientific community widely recognizes the urgent need for new TB vaccines. The global health implications of this research are profound. A therapeutic vaccine that shortens treatment, prevents relapse, and works against drug-resistant strains would be a game-changer for millions of lives annually. It could alleviate the burden on healthcare systems, reduce the spread of drug resistance, and significantly contribute to the WHO’s ambitious goals for TB eradication.

While the current findings are highly encouraging, researchers caution that the path to a licensed human vaccine is long and fraught with challenges. The complexity of the human immune system and the unique characteristics of M. tuberculosis mean that animal model results do not always perfectly translate to humans. Significant investment in funding, infrastructure, and international collaboration will be required to advance this vaccine through the rigorous stages of clinical development.

The Johns Hopkins research team behind this breakthrough includes a comprehensive roster of dedicated scientists: Tianyin Wang, Addis Yilma, Jennie Ruelas Castillo, James Gordy, Hannah Bailey, Darla Quijada, Kaitlyn Fessler, Rokeya Tasneen, Elisa M. Rouse Salcido, Farah Shamma, Harley Harris, Fengyixin Chen, Rowan Bates, Heemee Ton, Jacob Meza, Yangchen Li, Alannah Taylor, Jean Zheng, Jiaqi Zhang, Theodoros Karantanos, Amanda Maxwell, Eric Nuermberger, J. David Peske, Richard Markham, and Petros Karakousis, alongside lead author Styliani Karanika.

This vital study received federal funding from several National Institutes of Health grants (R01AI148710, K24AI143447, P30AI18436, K08AI174959, and P30CA006973), underscoring the strategic national importance of this research. Additional crucial support was provided by a Gilead HIV Research Scholar Award, a Johns Hopkins University Tuberculosis Research Advancement Center Developmental Award, a Center for HIV/AIDS Developmental Award from the Johns Hopkins University Center for AIDS Research, a Willowcraft Foundation Award, a Johns Hopkins University Clinician Scientist Award, and the Potts Memorial Foundation. The involvement of multiple funding bodies highlights the collaborative and multi-faceted nature of cutting-edge biomedical research. Notably, Karanika, Gordy, Markham, and Karakousis are listed as inventors on patent PCT/US2023/065584 for the Mip3α/relMtb vaccine, indicating the innovative and proprietary nature of this scientific advancement. The authors have reported no conflicts of interest, ensuring the integrity and objectivity of their findings.

In conclusion, the development of an intranasal DNA vaccine targeting TB persisters represents a beacon of hope in the protracted battle against tuberculosis. By specifically addressing the elusive drug-tolerant forms of the bacteria and leveraging the strategic advantages of mucosal immunity, this research opens new avenues for therapeutic intervention. While human trials are still on the horizon, the promising preclinical data underscore the potential of this innovative approach to significantly alter the landscape of TB treatment, offering a pathway towards shorter, more effective regimens and ultimately, a world free from the devastating impact of this ancient disease.